Cargando…
Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom
OBJECTIVES: Rituximab (RTX) may be a treatment option for children and young people with JIA, although it is not licensed for this indication. The aim of this study was to describe RTX use and outcomes among children with JIA. METHODS: This analysis included all JIA patients within the UK Biologics...
Autores principales: | Kearsley-Fleet, Lianne, Sampath, Sunil, McCann, Liza J, Baildam, Eileen, Beresford, Michael W, Davies, Rebecca, De Cock, Diederik, Foster, Helen E, Southwood, Taunton R, Thomson, Wendy, Hyrich, Kimme L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343463/ https://www.ncbi.nlm.nih.gov/pubmed/30358861 http://dx.doi.org/10.1093/rheumatology/key306 |
Ejemplares similares
-
Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2019) -
Factors associated with choice of first biologic among children with juvenile idiopathic arthritis: a combined analysis from two UK paediatric biologic registers
por: Davies, Rebecca, et al.
Publicado: (2014) -
Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2019) -
Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2016) -
Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2022)